Becton Dickinson and Co vs iShares MSCI India ETF — how do they compare? Becton Dickinson and Co trades at $155.79 (market cap $41.51B), while iShares MSCI India ETF trades at $48.76. The key difference: Becton Dickinson and Co pays a 2.79% dividend while iShares MSCI India ETF pays none. Which is the better fit depends on your goals.
| BDX | INDA | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $185.39 | $55.29 |
52-Week Low | $135.49 | $45.42 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
INDA trades at $48.79, down 1.03% with a bearish technical signal from moving averages. The India ETF faces mixed sentiment as India's economy grows at 7.8% (CNBC, 2026-06-05) but confronts headwinds from IT sector weakness and Middle East risks. Technical indicators show neutral oscillators with key support at $48.
Outlook remains cautious amid valuation concerns and macroeconomic pressures. Investment opportunity lies in India's long-term growth story, but risks include foreign outflows, geopolitical tensions, and sector-specific challenges in technology and energy transition.
Trailing returns across standard periods
Latest headlines on both assets
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →